Please try another search
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
Name | Age | Since | Title |
---|---|---|---|
Santosh Kesari | - | 2015 | Member of Scientific Advisory Board |
Claire Thom | 66 | 2016 | Independent Director |
Søren Brøgger Christensen | - | - | Member of Scientific Advisory Board |
Scott V. Ogilvie | 67 | 2008 | Independent Director |
Samuel R. Denmeade | - | - | Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board |
John T. Isaacs | - | - | Co-Founder, Chairman of Scientific Advisory Board & Chief Scientific Advisor |
Raul Silvestre | 51 | 2021 | CEO, CFO, President, Principal Accounting Officer & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review